NCT03307785: Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 or With TSR-042 and Bevacizumab

NCT03307785
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system metastases
https://ClinicalTrials.gov/show/NCT03307785

Comments are closed.

Up ↑